U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H27FN4O2.C4H6O5
Molecular Weight 532.5612
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of Sunitinib Malate

SMILES

O[C@@H](CC(O)=O)C(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C

InChI

InChIKey=LBWFXVZLPYTWQI-IPOVEDGCSA-N
InChI=1S/C22H27FN4O2.C4H6O5/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28;5-2(4(8)9)1-3(6)7/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28);2,5H,1H2,(H,6,7)(H,8,9)/b17-12-;/t;2-/m.0/s1

HIDE SMILES / InChI
Molecular Formula C4H6O5
Molecular Weight 134.0874
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED
Molecular Formula C22H27FN4O2
Molecular Weight 398.4738
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Approval Year

Unknown
86413
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:21:42 UTC 2023
Edited
by admin
on Fri Dec 15 16:21:42 UTC 2023
Record UNII
LVX8N1UT73
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Sunitinib Malate
JAN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN  
Official Name English
SUNITINIB MALATE [MART.]
Common Name English
SUNITINIB MALATE [ORANGE BOOK]
Common Name English
SUNITINIB MALATE [MI]
Common Name English
Sunitinib L-Malate
Common Name English
Butanedioic acid, hydroxy-, (2S)-, compd. with N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)
Systematic Name English
Butanedioic acid, 2-hydroxy-, (2S)-, compd. with N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)
Systematic Name English
SU010398
Code English
SUNITINIB MALATE [USAN]
Common Name English
PHA-290940AD
Code English
SUNITINIB MALATE [JAN]
Common Name English
SUTENT
Brand Name English
SU-010398
Code English
1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
Systematic Name English
SUNITINIB MALATE [VANDF]
Common Name English
Sunitinib malate [WHO-DD]
Common Name English
SU-011248 L-MALATE SALT
Code English
SU011248 L-MALATE SALT
Code English
Classification Tree Code System Code
NCI_THESAURUS C129825
Created by admin on Fri Dec 15 16:21:42 UTC 2023 , Edited by admin on Fri Dec 15 16:21:42 UTC 2023
EMA ASSESSMENT REPORTS SUTENT (AUTHORIZED: CARCINOMA , RENAL CELL)
Created by admin on Fri Dec 15 16:21:42 UTC 2023 , Edited by admin on Fri Dec 15 16:21:42 UTC 2023
EMA ASSESSMENT REPORTS SUTENT (AUTHORIZED: GASTROINTESTINAL STROMAL TUMORS)
Created by admin on Fri Dec 15 16:21:42 UTC 2023 , Edited by admin on Fri Dec 15 16:21:42 UTC 2023
NCI_THESAURUS C1967
Created by admin on Fri Dec 15 16:21:42 UTC 2023 , Edited by admin on Fri Dec 15 16:21:42 UTC 2023
NCI_THESAURUS C1971
Created by admin on Fri Dec 15 16:21:42 UTC 2023 , Edited by admin on Fri Dec 15 16:21:42 UTC 2023
Code System Code Type Description
FDA UNII
LVX8N1UT73
Created by admin on Fri Dec 15 16:21:42 UTC 2023 , Edited by admin on Fri Dec 15 16:21:42 UTC 2023
PRIMARY
RS_ITEM_NUM
1642358
Created by admin on Fri Dec 15 16:21:42 UTC 2023 , Edited by admin on Fri Dec 15 16:21:42 UTC 2023
PRIMARY
CAS
341031-54-7
Created by admin on Fri Dec 15 16:21:42 UTC 2023 , Edited by admin on Fri Dec 15 16:21:42 UTC 2023
PRIMARY
DRUG BANK
DBSALT000166
Created by admin on Fri Dec 15 16:21:42 UTC 2023 , Edited by admin on Fri Dec 15 16:21:42 UTC 2023
PRIMARY
RXCUI
616275
Created by admin on Fri Dec 15 16:21:42 UTC 2023 , Edited by admin on Fri Dec 15 16:21:42 UTC 2023
PRIMARY RxNorm
NCI_THESAURUS
C26673
Created by admin on Fri Dec 15 16:21:42 UTC 2023 , Edited by admin on Fri Dec 15 16:21:42 UTC 2023
PRIMARY
DAILYMED
LVX8N1UT73
Created by admin on Fri Dec 15 16:21:42 UTC 2023 , Edited by admin on Fri Dec 15 16:21:42 UTC 2023
PRIMARY
PUBCHEM
6456015
Created by admin on Fri Dec 15 16:21:42 UTC 2023 , Edited by admin on Fri Dec 15 16:21:42 UTC 2023
PRIMARY
EVMPD
SUB22366
Created by admin on Fri Dec 15 16:21:42 UTC 2023 , Edited by admin on Fri Dec 15 16:21:42 UTC 2023
PRIMARY
EU-Orphan Drug
EU/3/05/268(WITHDRAWN)
Created by admin on Fri Dec 15 16:21:42 UTC 2023 , Edited by admin on Fri Dec 15 16:21:42 UTC 2023
PRIMARY Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in July 2008 on request of the sponsor. On 10 March 2005, orphan designation (EU/3/05/268) was granted by the European Commission to Pfizer Limited, United Kingdom, for (Z)-N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (S)-2-hydroxysyccinate for the treatment of renal cell carcinoma. (Z)-N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (S)-2-hydroxysyccinate has been authorised in the EU as Sutent since 19 July 2006 for the treatment of advanced and/or metastatic renal cell carcinoma (MRCC) after failure of interferon alfa or interleukin-2 therapy.
EU-Orphan Drug
EU/3/05/267(WITHDRAWN)
Created by admin on Fri Dec 15 16:21:42 UTC 2023 , Edited by admin on Fri Dec 15 16:21:42 UTC 2023
PRIMARY Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in July 2008 on request of the sponsor. On 10 March 2005, orphan designation (EU/3/05/267) was granted by the European Commission to Pfizer Limited, United Kingdom, for (Z)-N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (S)-2-hydroxysyccinate for the treatment of malignant gastrointestinal stromal tumours. (Z)-N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (S)-2-hydroxysyccinate has been authorised in the EU as Sutent since 19 July 2006.
EPA CompTox
DTXSID4046492
Created by admin on Fri Dec 15 16:21:42 UTC 2023 , Edited by admin on Fri Dec 15 16:21:42 UTC 2023
PRIMARY
SMS_ID
100000093454
Created by admin on Fri Dec 15 16:21:42 UTC 2023 , Edited by admin on Fri Dec 15 16:21:42 UTC 2023
PRIMARY
ChEMBL
CHEMBL535
Created by admin on Fri Dec 15 16:21:42 UTC 2023 , Edited by admin on Fri Dec 15 16:21:42 UTC 2023
PRIMARY
USAN
QQ-94
Created by admin on Fri Dec 15 16:21:42 UTC 2023 , Edited by admin on Fri Dec 15 16:21:42 UTC 2023
PRIMARY
CHEBI
38940
Created by admin on Fri Dec 15 16:21:42 UTC 2023 , Edited by admin on Fri Dec 15 16:21:42 UTC 2023
PRIMARY
MERCK INDEX
m10399
Created by admin on Fri Dec 15 16:21:42 UTC 2023 , Edited by admin on Fri Dec 15 16:21:42 UTC 2023
PRIMARY Merck Index
Related Record Type Details
Structure of SUNITINIB
PARENT -> SALT/SOLVATE
Structure of MALIC ACID, L-
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of SUNITINIB
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966